NRAS News | 14 May 2018
The European Union has taken a monumental step in protecting the fundamental right to privacy for every EU resident with the General Data Protection Regulation (GDPR) which will be effective from May 25, 2018.
NRAS News | 26 Apr 2018
There is a big social stigma around Rheumatoid Arthritis (and other long term conditions) in South Asian communities! Research suggests South Asian people with RA are often forced to hide their condition due to society beliefs, misconceptions etc. Combined with language barriers, this can have a severe impact on their ability to receive accurate info and live a healthy life.
RA news | 23 Mar 2018
The Oxford Academic Health Science Network (Oxford AHSN) and Sandoz, have developed an informative animation on biosimilars with input from individuals living with inflammatory arthritis and in partnership with the National Rheumatoid Arthritis Society.
21 Mar 2018
A new campaign that highlights the importance of mental strength in helping people with RA manage their condition
NRAS News | 14 Feb 2018
NRAS Launches 'Love Your Heart' Interactive Video Programme. A new initiative aims to decrease cardiovascular risk for people with Rheumatoid Arthritis.
RA news | 2 Feb 2018
Earlier this week, the Department for Work and Pensions (DWP) announced that every person receiving Personal Independence Payments (PIP) will have their claim reviewed. This follows a court ruling that said changes to PIP were unfair to people with mental health conditions.
RA news | 26 Jan 2018
Getting an annual flu vaccine is recommended for people with RA, but if you do develop flu or live with someone who has it, the following advice issued to patients by Portsmouth Hospital’s Department of Rheumatology may be useful to you.
CIMZIA® label change marks an important advance for women in the UK of childbearing age with moderate to severe active rheumatoid arthritisRA news | 15 Jan 2018
The European Medicines Agency (EMA) has approved the label change for UCB’s CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with moderate to severe active rheumatoid arthritis, active psoriatic arthritis and ankylosing spondylitis during both pregnancy and breastfeeding.